As we approach the third decade since the WHO started addressing the eradication of poliomyelitis and leprosy, a reflection of the previous campaigns efficacy and an evaluation of further elimination feasibility is important to adapt and intensify the next steps. We performed a critical review of the poliomyelitis and leprosy eradication campaigns to evaluate their technical and operational feasibilities. Vaccination and active case search are highly effective tools against poliomyelitis. If political stability and good vaccination coverage is achieved, poliomyelitis will be an easy target for eradication. Leprosy, on the other hand, faces many barriers towards elimination. The lack of a high efficacy vaccine, the long asymptomatic but infective period, the lack of screening tests and a poorly established elimination target, prevents this disease from being eliminated. In a world where resources and funding are limited, it is apparent that poliomyelitis is a more feasible target for elimination than leprosy. Keywords: Communicable Disease Control; Disease Eradication; Leprosy; Poliomyelitis; Program Evaluation.
INTRODUCTION
The World Health Organization (WHO) has been defining strategic plans in order to provide nations with interventions for prevention, control, elimination and eradication of neglected tropical diseases since 1978. 1 Leprosy, a chronic debilitating infectious disease, whose causal agent is Mycobacterium leprae, is associated with deformity and physical disability leading to severe social stigma. The micro-organism is slow-growing and affects the skin and peripheral nerves and, although the disease has been discovered in wild animals, it is believed that humans are the main reservoir. Characterized by a long incubation period of 2-15 years, there is evidence supporting respiratory droplets as the transmission route. Lack of effective screening tests to identify subclinical infections makes case identification difficult and dependable on the clinicians' and patients' suspicion for any skin lesion associated with sensory loss.
Poliomyelitis is a faecal-oral transmitted disease caused by a small RNA poliovirus, characterized by an invasion of the nervous system with consequent acute flaccid paralysis (AFP). Irreversible paralysis in the lower limbs may occur in 1 of every 200 infections.
2 During the infectious period, the virus is shed in enormous quantities in the throat and intestines of infected individuals. 2 Two forms of poliomyelitis can be identified, one derived from wild-type poliovirus (WPV-1,2,3), responsible for the disease in endemic areas, and a vaccine-associated poliovirus (VAPV), associated with reactivation of the virus used in the oral vaccine. Case definition for both diseases by the WHO can be found in Table 1 .
Being both diseases targets for elimination by the WHO, the aim of this article is to reflect on the elimination programs and compare them in term disease eradicability.
MATERIAL AND METHODS
A structured search to identify publications on the elimination strategies was performed on PubMed ® . The keywords used were "leprosy", "poliomyelitis", "elimination", "eradication" and "campaigns". The search identified 198 leprosy-related and 1598 polio-related journal publications. The initial approach was to identify 5 review articles for each disease for an overall understanding followed by a more specific selection to identify potential publications focusing on elimination. were also scanned. Terms were defined by the WHO criteria: control -reduction of disease incidence to a locally acceptable level, elimination -reduction of the incidence of infection to zero, eradication -permanent worldwide reduction of infection to zero, basic reproductive rate (R0) -number of secondary infectious cases produced by a single infectious case in a susceptible population. 3 The criteria used for assessing the feasibility of disease elimination can be found in Table 2 . Ethical committee approval was not necessary as no data from patients was collected.
RESULTS

The way to elimination A) Campaigns for Poliomyelitis
In 1988, a Global Polio Eradication Initiative (GPEI) was created by the WHO to eliminate WPV as it was endemic in 125 countries, with an estimated global prevalence of 10-12 million cases every year. 4 The strategy aimed at the interruption of endemic transmission of poliovirus having four key points: herd immunization through vaccination, booster immunization, active case finding and surveillance and "mop-up" campaigns in focal high-endemic areas. 5 A sequence of successes was noticed soon after: eradication of polio in Peru by 1991, the Americas in 1994, the Western Pacific Region in 2000 and Europe in 2002. [6] [7] [8] Poliomyelitis was further eliminated from Niger and Egypt, but by the year 2006 it still remained endemic in four countries: Pakistan, Afghanistan, India and Nigeria, with several outbreaks due to imported cases occurring in previously polio-free countries.
The last country to achieve elimination was India, in 2012, leaving the world with only 3 countries reporting endemic poliomyelitis. The path to elimination requires a timely approach to the needs of a country, as was seen in the successful Indian elimination campaign. Some years after the start of the vaccination program, eradication of the WPV-2 was achieved with the trivalent OPV (tOPV), which had a higher efficacy against this serotype. However, even after a 94% vaccine coverage was achieved, more than 95% of the children with active poliomyelitis had in fact received at least 4 tOPV doses earlier on, revealing the extremely poor efficacy of the trivalent vaccine on the other serotypes 9 . The last cases of WPV-3 in 2010 and WPV-1 in 2011 only occurred after the introduction of the higher efficacy monovalent wild-polio virus-1 and 2 (WPV-1 and WPV-2) vaccines in 2007, and later on, the bivalent OPV (bOPV). These efforts, however, were only achieved in association with efficient mapping of high-risk blocks in hyperendemic regions, better sanitation and an "active surveillance" program of children under-15 with AFP. 10 Vaccination regimens and coverage were maintained and India was finally considered free of wild-type poliomyelitis after 2 years of null cases of AFP and negative sewage waters in major Indian cities for WPV.
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B) Campaigns for Leprosy
The elimination of leprosy was defined by the WHO as the reduction of the number of cases to less than 1 case per 10.000 population assuming that it would prevent transmission. The strategy was to establish specific Table 1 -World Health Organization case definitions for leprosy and poliomyelitis
Leprosy Poliomyelitis
Presence of one of the following: · Loss of sensation in pale or reddish skin lesions · Peripheral nerves with loss of sensation or weakness of the muscles supplied by that nerve · Acid fast bacilli in a slit skin smear sample · Child < 15 years of age presenting with acute flaccid paralysis (AFP) Or · Any person at any age with paralytic illness if poliomyelitis is suspected Plus · Isolation of wild poliovirus in stool specimen of a suspected case or contact Table 2 -Criteria for assessing the eradicability of a disease · Need for eradication rather than control programs such as the Leprosy Elimination Campaigns (LEC) which were based in enhanced diagnosis, provision of free multi-drug treatment (MDT) (rifampicin, clofazimine and dapsone), follow-up care, community based counselling and education in order to reduce stigma while increasing self-report. 12 These sole efforts managed to reduce the disease prevalence to 2.7 million by 1994.
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At the beginning of 2013, the WHO reports revealed that the current global prevalence of leprosy stood at 189.018 cases, while the incidence during 2012 was 232.857. 14 This incidence derives from high-endemic foci like Angola, Brazil and India, with some countries considered to have eliminated leprosy such as the Democratic Republic of Congo (DRC) and Mozambique also exhibiting some high endemicity foci.
DISCUSSION
When comparing leprosy and poliomyelitis elimination campaigns, both technical and operational feasibility should be assessed. Technical feasibility depends on the disease biology and interventions efficacy to interrupt disease transmission; operational feasibility depends on human capital, infrastructures, and political commitment in order to reach the elimination goals. Table 3 resumes the biological characteristics of both diseases on which technical feasibility depends.
Technical Feasibility
Epidemiological susceptibility -While both diseases have good diagnostic criteria for active disease and no relevant non-human reservoir, they differ in infectivity. Poliomyelitis is a self-limited disease, and viral shedding has a limited duration, while leprosy is a chronic disease, and probably infective throughout the whole disease process. Leprosy also lacks reliable laboratory tests to detect subclinical infection, which renders it harder to diagnose when asymptomatic, but still infective. The incubation period may be as long as 2-15 years and new patients may continue to present after successful control campaigns have ended.
However, while poliomyelitis is highly infective, with an estimated R0 as high as 10-15, in a non-vaccinated population with circulating WPV, the basic reproductive rate for leprosy has not been previously estimated since there is no universally accepted test for subclinical infection. However it is estimated to be 1.5-4, depending on the setting.
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Practical interventions' availability -While a curative approach does not exist for poliomyelitis, being the treatment supportive, several vaccines with different efficacies addressing the three serotypes exist and are available. On the other hand, leprosy has no vaccination available, but it has an available treatment with 98% efficacy.
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Treatment for leprosy with MDT not only has a high efficacy, but also shortens the duration of infectivity and therefore reduces the risk of further transmission to healthy individuals in the community.
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An aspect to remember is that, to achieve true polio eradication, transmission should be zero not only for WPVs but also VAPV. Even though rarely (one case per 750 000 doses), tOPV is associated with vaccine-induced paralysis as the attenuated virus may mutate and regain neurovirulence and transmissibility. [18] [19] [20] After WPV elimination, it is no longer correct to continue immunization with OPV and therefore it should be substituted with the inactivated poliovirus vaccine (IPV), especially in countries using bOPV, which does not confer immunity against a re-emergence of WPV-2. Even though IPV is more expensive and does not confer strong herd immunity, it is efficient against all types of WPV. 15 Nevertheless, eradication will only be achievable if after elimination, vaccination programs are maintained to keep herd immunity against imported cases.
It has been suggested that Bacillus Calmette-Guérin vaccine could help the leprosy campaigns, but as it is Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com already widespread in endemic countries, may not be as useful as expected.
Operational feasibility
While both diseases had a high prevalence and high morbidity rates associated, which targeted them for elimination by the WHO, previous elimination campaigns have shown that they greatly depend on the setting and political and social support.
In 2012, three countries were still considered to be polioendemic: Nigeria and Pakistan with WPV types 1 and 3 and Afghanistan with WPV type 1. General operational reasons identified during the last 20 years that prevent eradication can be found in Table 4 , as well as some solutions. 20 It seems that the most important factor for delaying eradication is poor vaccination coverage of the paediatric population. Reasons are migration, isolated populations and regions where conflict is apparent such as Pakistan and Southern Afghanistan, where vaccination campaigns are often cancelled or not planned due to safety reasons.
During the past decade, 40 countries developed outbreaks of poliomyelitis due to imported WPVs. As long as WPVs circulate anywhere, these may re-infect polio-free countries. These aspects reveal that operational feasibility is highly dependent on political stability and support to block importation of new cases post-elimination.
Leprosy campaigns committed governments, donors, and health workers to focus on leprosy and facilitated free drug treatment. 22 However, the last WHO report on the Global Leprosy situation showed that, not only incidence has not significantly dropped since 2005 but also that the proportion of patients presenting with advanced disability is still high.
14 As elimination was not defined to be zero cases, many countries where elimination was achieved still report new cases every year, as transmission is not truly interrupted despite the public perception of elimination. In Peru, for instance, the loss of active-case search and contact screening, lead to occult leprosy prevalence and patients presenting late in their disease. Lockwood et al, recently addressed the Brazilian omission of active cases in order to fulfil the WHO objectives of elimination. Her reflections suggested that objectives must be transparent as workers aim to reach targets in the most unexpected ways, with the penalty of compromising the campaigns efforts.
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Given this, one of the key objectives of the current leprosy plan is to keep treating all people who have this disease, and that, even though a country may achieve elimination as defined by the WHO, further campaigns are still needed and should not be forgotten by the authorities and donors after elimination. As we are approaching the third decade since the WHO began addressing these problems, a reflection on the previous campaigns efficacy and an evaluation of further elimination feasibility is important to adapt and intensify the following steps. The world has great tools against poliomyelitis as vaccination and active-case search are highly effective. If political stability and good vaccination coverage is achieved, in the next years, poliomyelitis will be a great candidate for eradication. Leprosy, on the other hand, faces many barriers towards elimination. The lack of a high efficacy vaccine, the long asymptomatic but infective period, the lack of screening tests and a poorly established elimination target, delays the elimination of this disease. In a world where resources and funding are limited, it is apparent that poliomyelitis is a more feasible target for elimination than leprosy. As for the latter, in order to achieve elimination, campaign remodelling and intensification, with long lasting screening, active case search, and reasonable targets, adapted to a disease with a long incubation period, should be defined. However, it seems that it will take long until we reach true elimination.
CONCLUSIONS
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